- ChromaDex wins orphan designation for rare ataxia drug
- Intra-erythrocyte infusion of dexamethasone reduces neurological symptoms in ataxia teleangiectasia patients: results of a phase 2 trial.
- Quince Therapeutics doses first subject in Ataxia-Telangiectasia trial
- To Evaluate the Effects of EryDex in Patients With A-T (NEAT)
- U.S. FDA Partial Clinical Hold Lifted on IND for EryDel’s Lead Phase 3 Asset EryDex for the Treatment of Ataxia-Telangiectasia
